Havana, August 31 (RHC) After a week of follow-up to the first volunteers, the research team of the Cuban vaccine candidate against Covid-19 is delivering this Monday the files to the regulatory entity to request going up to the next step of the clinical trial in phase I.
The first group, integrated by 20 individuals from 19 to 59 years of age, was vaccinated a week ago to evaluate the candidate's safety.
According to the developers, all of them are in good health.
The only adverse effect they experienced was mild pain at the injection site, a common side effect for all vaccines.
After this step, the Center for the State Control of Medicines (Cecmed), the regulatory entity, is expected to give the green light to the vaccination of the second planned group, integrated by the same amount of volunteers, but with ages ranging from 60 to 80 years old.
The vaccine candidate is called Soberana 01, and it is developed by the Finlay Institute of Vaccines (IFV). It is in its first phase of clinical trials in humans after showing positive results in the pre-clinical stage in animals.